期刊文献+

瑞舒伐他汀对PCI术后患者APN和hs-CRP的影响 被引量:3

Effect of Rosuvastatin on Serum APN and Hs-CRP in Patients after Percutaneous Coronary Intervention
暂未订购
导出
摘要 目的探讨瑞舒伐他汀对经皮冠状动脉介入术(percutaneous coronary intervention,PCI)后患者血清脂联素(adiponectin,APN)和超敏C反应蛋白(high sensitivity C-reactive protein,hs-CRP)的影响。方法 108例成功进行PCI治疗的患者随机分为两组。对照组46例仅常规治疗,瑞舒伐他汀处理组62例在常规治疗基础上,每晚口服瑞舒伐他汀10 mg。观察PCI术前、术后1天、1月、3月、6月血APN及hs-CRP水平,并进行比较和相关分析。结果两组PCI术前及术后1天血APN和hs-CRP水平差异无统计学意义(P>0.05)。术后1月、3月、6月与术后1天相比,两组血APN水平均升高,hs-CRP水平均下降;与对照组比较,瑞舒伐他汀组术后血APN水平明显升高,而hs-CRP水平显著下降,差异均有统计学意义(P<0.01)。血APN与hs-CRP水平呈负相关(r=-0.330,P<0.05)。结论瑞舒伐他汀在冠状动脉支架植入术后能显著提高血APN水平,降低hs-CRP水平,预防和延缓PCI术后再狭窄。 Objective To investigate the effect of rosuvastatin on serum adiponectin(APN) and high-sensitivity C-reactive protein(hs-CRP) on patients after percutaneous coronary intervention(PCI).Methods One hundred and eight patients with successful PCI were randomly divided into control group(46 cases) accepting conventional therapy and rosuvastatin group(62 cases) with oral administration of 10mg rosuvastatin each night besides the conventional therapy.Serum APN levels and hs-CRP levels were observed before PCI,one day,1 month,3 months and 6 months after PCI.Comparison and correlation analysis was performed.Results There was no significant difference in serum APN and hs-CRP levels between the two groups before PCI and one day after PCI(P0.05).Serum APN levels were significantly increased and hs-CRP levels were obviously decreased in two groups 1 month,3 months and 6 months after intervention compared with those 1 day after PCI.Serum APN concentration was significantly higher in rosuvastatin group than that in control group,and blood hs-CRP level was significantly lower than that in control group(P0.01).The blood APN levels were negatively related with hs-CRP levels(r=-0.330,P0.05).Conclusion Rosuvastatin can significantly improve serum APN levels and decrease hs-CRP levels in the patients with coronary stent implantation so as to prevent and delay restenosis after PCI.
出处 《华南国防医学杂志》 CAS 2011年第6期506-508,共3页 Military Medical Journal of South China
基金 全军医学科学技术"十一五"计划课题(调整项目)
关键词 瑞舒伐他汀 冠状动脉支架植入术 超敏C反应蛋白 脂联素 Rosuvastatin Coronary stent implantation High-sensitivity C-reactive protein Adiponectin
  • 相关文献

参考文献10

  • 1Han B,Chanin D,Peleg A,et al.Loss of system in endothelialfunction post-PCI[J].Acute Card Care,2008,10(2):79-87
  • 2Yun KH,Jeong MH,Oh SK,et al.Response of high-sensitivityC-reactive protein to percutaneous coronary intervention in pa-tients with acute coronary syndrome[J].Heart Vessels,2009,24(3):175-180
  • 3Mazaki-Tovi S,Romero R,Vaisbuch E,et al.Low circulatingmaternal adiponectin in patients with pyelonephritis:adiponectinat the crossroads of pregnancy and infection[J].J Perinat Med,2010,38(1):9-17
  • 4Li JJ,Ren Y,Chen KJ,et al.Impact of C-reactive protein on in-stent restenosis:a meta-analysis[J].Tex Heart Inst J,2010,37(1):49-57
  • 5Nusea A,Melfi R,Di Seiaseio C.Percutaneous coronary inter-ventions and statin therapy[J].Ther Adv Cardiovase Dis,2008,2(2):101-107
  • 6Park DW,Lee CW,Yun SC,et al.Prognostic impact of prepro-cedural C-reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation[J].Heart,2007,9(3):1087-1092
  • 7Ferri C,Croee G,Cofini V,et al.C-reactive protein:interactionwith the vascular endothelium and possible role in human athero-sclerosis[J].Current Pharmaccutical Design,2007,13(16):1631-1645
  • 8Hubacek J,Basran RS,Shrive FM,et al.Prognostic inplicationsof C-reactive protein and troponin following percutaneous coro-nary intervention[J].Can J Cardiol,2009,25(2):42-47
  • 9Shioji K,Moriwaki S,Takeuchi Y,et al.Relationship of serumadiponectin level to adverse cardiovascular events in patients whoundergo percutaneous coronary intervention[J].Circ J,2007,7(5):675-680
  • 10袁国跃,周丽斌,唐金凤,杨颖,顾卫琼,李凤英,洪洁,顾燕云,徐敏,杜鹏飞,李小英,宁光,陈名道.糖耐量受损和2型糖尿病患者血清C反应蛋白与胰岛素敏感指数、脂联素的关系[J].中华内分泌代谢杂志,2005,21(6):507-510. 被引量:50

二级参考文献18

  • 1朱麒钱,尤巧英,李成江,李红,沈建国,斯徐伟,官莉莉,俞钟明,楼大均,金华伟.C反应蛋白与2型糖尿病大血管病变危险因素的相关性研究[J].中华内分泌代谢杂志,2005,21(4):320-321. 被引量:105
  • 2Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vase Biol, 1998,18 : 1386-1392.
  • 3Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984 1998. Arch Intern Med, 2003,163:93-99.
  • 4Aronson D, Bartha P, Zinder O, et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med, 2004,21:39-44.
  • 5Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000,96 : 1723-1732.
  • 6Yamauehi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 2001,7:941-946.
  • 7Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001,86:1930-1935.
  • 8Liudsay RS, Funahashi T, Hanson RL, et al. Adiponectin protects against development of type 2 diabetes in the Pima Indian population. Lancet, 2002,360:57-58.
  • 9O'Riordain MG, Ross JA, Fearon KC, et al. Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol, 1995,269 : E323-330.
  • 10Temelkova-Kurktschiev T, Henkel E, Koehler C, et al. Subclinical inflammation in newly detected type Ⅱ diabetes and impaired glucose tolerance. Diabetologia, 2002,45 : 151.

共引文献49

同被引文献23

  • 1王志兴.辛伐他汀与瑞舒伐他汀对心肌梗死患者PCI后血浆NT-proBNP、MMP-2表达及左室重构作用比较[J].湖北医药学院学报,2011,30(4):394-396. 被引量:6
  • 2项延郡,周达新.瑞舒伐他汀对急性心肌梗死患者血清炎症因子和脂联素水平的影响[J].中国临床药学杂志,2012,3(5):454l-4542.
  • 3Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction[J]. Am Heart J, 2001, 141 (3) :367-374.
  • 4Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early pereutaneous coronary intervention: results of the ARMYDA- ACS randomized trial[J]. J Am Coil Cardiol,2007,49(12) : 1272-1278.
  • 5Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome[J]. Int J Cardiol, 2009, 137 (3) :246-251.
  • 6Brewer HB Jr.- Benefit-risk assessment of rosuvastatin 10 to 40 milligrams[J]. Am J Cardiol, 2003, 92(4B): 23-29.
  • 7Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac: function and symptoms in patients with idiopathic dilated cardiomyopathy[J]. Circulation, 2003, 108 (7) : 839-843.
  • 8G O A S,CHERTOW G M, FAN D,et al. Chronic kidney disease and the risks of deach, cardiovascular events, and hospitalization [J]. N Engl J Med,2004,351:1296 - 1305.
  • 9NISHIZAWA Y, SHOJI T, KAKIYA R, et al. Non - high - density lipoprotein cholesterol( non - HDL) as cardiovascular mortality in patients with end -stage renal disease[ J], Kidney Int Suppl,2003 (84) :Sl17 - S120.
  • 10叶晴,朱柳莹,王琳.在线监测尿素清除率评价血液透析充分性的研究[J].现代医学,2012,12(6):28-29.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部